Drug-Drug Interactions in Patients with Acute Respiratory Distress Syndrome

Acute respiratory distress syndrome (ARDS) is a potential life-threatening, heterogenous, inflammatory lung disease. There are no data available on potential drug-drug interactions (pDDIs) in critically ill patients with ARDS. This study analyzed pDDIs in this specific cohort and aimed to investigat...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics 2024-02, Vol.16 (3), p.303
Main Authors: Bischof, Thorsten, Schaller, Christoph, Buchtele, Nina, Staudinger, Thomas, Ullrich, Roman, Kraft, Felix, Andersson, Marine L, Jilma, Bernd, Schoergenhofer, Christian
Format: Article
Language:English
Subjects:
Acute respiratory distress syndrome
coronavirus disease 2019
Coronaviruses
COVID-19
Drug interactions
Drug therapy
Drug therapy, Combination
Extracorporeal membrane oxygenation
Farmakologi och toxikologi
Hospitals
Intensive care
intensive care unit
Medical research
Medicin och hälsovetenskap
Medicine, Experimental
Medicinska och farmaceutiska grundvetenskaper
Patients
Polymerase chain reaction
potential drug–drug interactions
Respiratory distress syndrome
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Acute respiratory distress syndrome (ARDS) is a potential life-threatening, heterogenous, inflammatory lung disease. There are no data available on potential drug-drug interactions (pDDIs) in critically ill patients with ARDS. This study analyzed pDDIs in this specific cohort and aimed to investigate possible associations of coronavirus disease 2019 (COVID-19) as an underlying cause of ARDS and treatment with extracorporeal membrane oxygenation (ECMO) with the occurrence of pDDIs. This retrospective study included patients ≥18 years of age diagnosed with ARDS between January 2010 and September 2021. The Janusmed database was used for the identification of pDDIs. A total of 2694 pDDIs were identified in 189 patients with a median treatment duration of 22 days. These included 323 (12%) clinically relevant drug combinations that are best avoided, corresponding to a median rate of 0.05 per day. There was no difference in the number of pDDIs between COVID-19- and non-COVID-19-associated ARDS. In patients treated with ECMO, the rate of the most severely graded pDDIs per day was significantly higher compared with those who did not require ECMO. PDDIs occur frequently in patients with ARDS. On average, each patient may encounter at least one clinically relevant drug combination that should be avoided during their intensive care unit stay.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics16030303